181 related articles for article (PubMed ID: 33904236)
1. Enhancing anti-PD-1 Immunotherapy by Nanomicelles Self-Assembled from Multivalent Aptamer Drug Conjugates.
Geng Z; Wang L; Liu K; Liu J; Tan W
Angew Chem Int Ed Engl; 2021 Jul; 60(28):15459-15465. PubMed ID: 33904236
[TBL] [Abstract][Full Text] [Related]
2. Reducing Toxicity of Immune Therapy Using Aptamer-Targeted Drug Delivery.
Gilboa E; Berezhnoy A; Schrand B
Cancer Immunol Res; 2015 Nov; 3(11):1195-200. PubMed ID: 26541880
[TBL] [Abstract][Full Text] [Related]
3. Tumor-Targeted Nanomedicine for Immunotherapy.
Cabral H; Kinoh H; Kataoka K
Acc Chem Res; 2020 Dec; 53(12):2765-2776. PubMed ID: 33161717
[TBL] [Abstract][Full Text] [Related]
4. Aptamer-guided nanomedicines for anticancer drug delivery.
Alshaer W; Hillaireau H; Fattal E
Adv Drug Deliv Rev; 2018 Sep; 134():122-137. PubMed ID: 30267743
[TBL] [Abstract][Full Text] [Related]
5. Anti-PD-L1 DNA aptamer antagonizes the interaction of PD-1/PD-L1 with antitumor effect.
Gao T; Mao Z; Li W; Pei R
J Mater Chem B; 2021 Jan; 9(3):746-756. PubMed ID: 33319876
[TBL] [Abstract][Full Text] [Related]
6. Poly(ethylene glycol) shell-sheddable TAT-modified core cross-linked nano-micelles: TAT-enhanced cellular uptake and lysosomal pH-triggered doxorubicin release.
Zhang Y; Xiao Y; Huang Y; He Y; Xu Y; Lu W; Yu J
Colloids Surf B Biointerfaces; 2020 Apr; 188():110772. PubMed ID: 31999965
[TBL] [Abstract][Full Text] [Related]
7. Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy.
Yang Q; Shi G; Chen X; Lin Y; Cheng L; Jiang Q; Yan X; Jiang M; Li Y; Zhang H; Wang H; Wang Y; Wang Q; Zhang Y; Liu Y; Su X; Dai L; Tang M; Li J; Zhang L; Qian Z; Yu D; Deng H
Theranostics; 2020; 10(18):8382-8399. PubMed ID: 32724476
[TBL] [Abstract][Full Text] [Related]
8. Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer.
Camorani S; Passariello M; Agnello L; Esposito S; Collina F; Cantile M; Di Bonito M; Ulasov IV; Fedele M; Zannetti A; De Lorenzo C; Cerchia L
J Exp Clin Cancer Res; 2020 Sep; 39(1):180. PubMed ID: 32892748
[TBL] [Abstract][Full Text] [Related]
9. Aptamer-Gold Nanocage Composite for Photoactivated Immunotherapy.
Song W; Hu JJ; Song SJ; Xu Y; Yang H; Yang F; Zhou Y; Yu T; Qiu WX
ACS Appl Mater Interfaces; 2022 Sep; 14(38):42931-42939. PubMed ID: 36099584
[TBL] [Abstract][Full Text] [Related]
10. Aptamer-based self-assembled nanomicelle enables efficient and targeted drug delivery.
Chen G; Mao D; Wang X; Chen J; Gu C; Huang S; Yang Y; Zhang F; Tan W
J Nanobiotechnology; 2023 Nov; 21(1):415. PubMed ID: 37946192
[TBL] [Abstract][Full Text] [Related]
11. Aptamer-PROTAC Conjugates (APCs) for Tumor-Specific Targeting in Breast Cancer.
He S; Gao F; Ma J; Ma H; Dong G; Sheng C
Angew Chem Int Ed Engl; 2021 Oct; 60(43):23299-23305. PubMed ID: 34240523
[TBL] [Abstract][Full Text] [Related]
12. Cas9-edited immune checkpoint blockade PD-1 DNA polyaptamer hydrogel for cancer immunotherapy.
Lee J; Le QV; Yang G; Oh YK
Biomaterials; 2019 Oct; 218():119359. PubMed ID: 31349094
[TBL] [Abstract][Full Text] [Related]
13. Selective antitumor activity of drug-free TPGS nanomicelles with ROS-induced mitochondrial cell death.
Fan Z; Jiang B; Shi D; Yang L; Yin W; Zheng K; Zhang X; Xin C; Su G; Hou Z
Int J Pharm; 2021 Feb; 594():120184. PubMed ID: 33340597
[TBL] [Abstract][Full Text] [Related]
14. Combining Nanomedicine and Immunotherapy.
Shi Y; Lammers T
Acc Chem Res; 2019 Jun; 52(6):1543-1554. PubMed ID: 31120725
[TBL] [Abstract][Full Text] [Related]
15. PD-1 Blockade for Improving the Antitumor Efficiency of Polymer-Doxorubicin Nanoprodrug.
Gao F; Zhang C; Qiu WX; Dong X; Zheng DW; Wu W; Zhang XZ
Small; 2018 Sep; 14(37):e1802403. PubMed ID: 30129176
[TBL] [Abstract][Full Text] [Related]
16. Aptamer-based targeted therapy.
Zhu G; Chen X
Adv Drug Deliv Rev; 2018 Sep; 134():65-78. PubMed ID: 30125604
[TBL] [Abstract][Full Text] [Related]
17. Multifunctional aptamer-silver conjugates as theragnostic agents for specific cancer cell therapy and fluorescence-enhanced cell imaging.
Li H; Hu H; Zhao Y; Chen X; Li W; Qiang W; Xu D
Anal Chem; 2015 Apr; 87(7):3736-45. PubMed ID: 25686206
[TBL] [Abstract][Full Text] [Related]
18. Applications of Cancer Cell-Specific Aptamers in Targeted Delivery of Anticancer Therapeutic Agents.
Kim M; Kim DM; Kim KS; Jung W; Kim DE
Molecules; 2018 Apr; 23(4):. PubMed ID: 29617327
[TBL] [Abstract][Full Text] [Related]
19. Aptamer-Functionalized and Backbone Redox-Responsive Hyperbranched Polymer for Targeted Drug Delivery in Cancer Therapy.
Zhuang Y; Deng H; Su Y; He L; Wang R; Tong G; He D; Zhu X
Biomacromolecules; 2016 Jun; 17(6):2050-62. PubMed ID: 27113017
[TBL] [Abstract][Full Text] [Related]
20. A TIM-3 Oligonucleotide Aptamer Enhances T Cell Functions and Potentiates Tumor Immunity in Mice.
Gefen T; Castro I; Muharemagic D; Puplampu-Dove Y; Patel S; Gilboa E
Mol Ther; 2017 Oct; 25(10):2280-2288. PubMed ID: 28800954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
